月経困難症治療の世界市場（2022年～2028年）

世界の月経困難症治療の市場規模は、予測期間中に8.1%のCAGRで成長すると予想されています。月経周期を通じて痛みを和らげるための医薬品や薬剤の使用の増加、女性の健康に対する政府の意識向上への取り組みの活発化は、市場の成長を後押ししています。しかし、長期間の治療、罹患率、伝統的な家族の価値観が市場の成長を抑制すると考えられます。

当レポートでは、世界の月経困難症治療市場について調査分析し、市場概要、競合情勢、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向

第3章 競合情勢

• 競合ダッシュボード
• 主要戦略分析
• 主要企業分析

第4章 市場決定要因

• 促進要因
• 抑制要因
• 機会

第5章 市場セグメンテーション

• 世界の月経困難症治療市場：治療タイプ別
  • 非ステロイド系抗炎症薬（NSAID）
  • ホルモン療法
• 世界の月経困難症治療市場：タイプ別
  • 原発性月経困難症
  • 続発性月経困難症

第6章 地域分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • ASEAN諸国
  • 韓国
  • その他アジア太平洋
• 世界のその他の地域

第7章 企業プロファイル

• Bayer AG
• F. Hoffmann-La Roche Ltd
• SANOFI
• Alvogen Iceland
• Pfizer Inc.
• ObsEva
• Nobelpharma Co., Ltd
• Color Seven Co., Ltd.
• Sun Pharmaceutical Industries Limited
• Beurer GmbH
• Abbott Laboratories
• Taj Pharmaceuticals Ltd
• Myovant Sciences GmbH
• AbbVie Inc.
• Janssen Pharmaceuticals, Inc.
• At Lupin Inc.
• Cumberland Pharmaceuticals Inc.
• BioElectronics Corporation
• GlaxoSmithKline plc.
• Merck & Co., Inc.

LIST OF TABLES

• 1. GLOBAL DYSMENORRHEA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
• 2. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 3. GLOBAL HORMONAL THERAPY MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
• 4. GLOBAL DYSMENORRHEA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
• 5. GLOBAL DYSMENORRHEA TREATMENT FOR PRIMARY DYSMENORRHEA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 6. GLOBAL DYSMENORRHEA TREATMENT FOR SECONDARY DYSMENORRHEA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 7. GLOBAL DYSMENORRHEA TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
• 8. NORTH AMERICAN DYSMENORRHEA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
• 9. NORTH AMERICAN DYSMENORRHEA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
• 10. NORTH AMERICAN DYSMENORRHEA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
• 11. EUROPEAN DYSMENORRHEA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
• 12. EUROPEAN DYSMENORRHEA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
• 13. EUROPEAN DYSMENORRHEA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
• 14. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
• 15. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
• 16. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
• 17. REST OF THE WORLD DYSMENORRHEA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
• 18. REST OF THE WORLD DYSMENORRHEA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL DYSMENORRHEA TREATMENT MARKETMARKET, 2021-2028 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL DYSMENORRHEA TREATMENT MARKETMARKET BY SEGMENT, 2021-2028 (% MILLION)

• 3. RECOVERY OF GLOBAL DYSMENORRHEA TREATMENT MARKETMARKET, 2021-2028 (%)
• 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SHARE BY TREATMENT TYPE, 2021 VS 2028 (%)
• 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SHARE BY TYPE, 2021 VS 2028 (%)
• 6. GLOBAL DYSMENORRHEA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) TREATMENT TYPE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 8. GLOBAL HORMONAL THERAPY TREATMENT TYPE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 9. GLOBAL DYSMENORRHEA TREATMENT FOR PRIMARY DYSMENORRHEA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 10. GLOBAL DYSMENORRHEA TREATMENT FOR SECONDARY DYSMENORRHEA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 11. US DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
• 12. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
• 13. UK DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
• 14. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
• 15. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
• 16. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
• 17. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
• 18. ROE DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
• 19. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
• 20. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
• 21. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
• 22. ASEAN DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
• 23. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
• 24. REST OF ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
• 25. REST OF THE WORLD DYSMENORRHEA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)

Global Dysmenorrhea treatment Market Size, Share & Trends Analysis Report by Treatment Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Hormonal Therapy), By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea) Forecast Period 2022-2028

The global market for dyes & pigments is projected to have a considerable CAGR of around 8.1% during the forecast period. Dysmenorrhea is the medical name for the pain that women experience during their menstrual cycle. It refers to strong cramps that start in the lower abdomen and spread to the back and lower legs. The majority of women begin to experience extreme pain in their early adolescence, roughly five years after the menstrual cycle begins. Increased health awareness among women to combat dysmenorrhea has resulted from an increase due to the occurrence of the condition. As a result, the use of pharmaceuticals and medicines to relieve the pain throughout the menstrual cycle has increased, and this, in turn, increases the global market's growth. Companies in the market have launched innovative drugs for treating dysmenorrhea. Furthermore, the global dysmenorrhea treatment market is growing due to a rise in government awareness initiatives about women's health. However, long-term treatment, morbidity, and traditional family values would restrain the growth of the market.

The global dysmenorrhea treatment market is segmented based on treatment types, and type. Based on the treatment types, the market is further classified as non-steroidal anti-inflammatory drugs (NSAIDs), and, hormonal therapy. Further, based on the type the market is classified into primary dysmenorrhea, and secondary dysmenorrhea. Among this primary dysmenorrhea is anticipated to dominate the market growth due to increasing advancement in the technology and growing use of medication and also due to the high adoption of OTC menstrual cramps treatment among the patients.

Geographically market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is projected to dominate the global dysmenorrhea treatment market during the forecast period resulting from well-established health care infrastructure and high awareness in the region. Further, Asia-Pacific is expected to be the fastest-growing market due to an increase in purchasing power, improving infrastructure, and a rise in awareness about clinical facilities are likely to fuel the growth of the market in the region.

The key players of the market include Siemens Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi among others. These market players adopt various strategies such as product launches, partnerships, collaborations, mergers, and acquisitions to sustain a strong position in the market. In September 2019, Bayer announced data demonstrating that a single maximum non-prescription dose of Aleve provided more pain relief over 12 hours than acetaminophen for menstrual cramps due to primary dysmenorrhea.

Research Methodology

The market study of the global dysmenorrhea treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

• Financial reports of companies involved in the market.
• Whitepapers, research papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global dysmenorrhea treatment Market Research and Analysis by Treatment Type

2. Global dysmenorrhea treatment Market Research and Analysis by Type

The Report Covers:

• Comprehensive Research Methodology of the global dysmenorrhea treatment market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the global d dysmenorrhea treatment market.
• Insights about market determinants that are stimulating the global dysmenorrhea treatment market.
• Detailed and extensive market segments with the regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players

Table of Contents

1. Report Summary

• 1.1. Research Methods and Tools
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Dysmenorrhea Treatment Industry
• Recovery Scenario of Global Dysmenorrhea Treatment Industry
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Geography

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Competitive Dashboard
• 3.2. Key Strategy Analysis
• 3.3. Key Company Analysis
  • 3.3.1.1. Overview
  • 3.3.1.2. Financial Analysis
  • 3.3.1.3. SWOT Analysis
  • 3.3.1.4. Recent Developments

4. Market Determinants

• 4.1. Motivators
• 4.2. Restraints
• 4.3. Opportunities

5. Market Segmentation

• 5.1. Global Dysmenorrhea Treatment Market by Treatment Type
  • 5.1.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • 5.1.2. Hormonal Therapy
• 5.2. Global Dysmenorrhea Treatment Market by Type
  • 5.2.1. Primary Dysmenorrhea
  • 5.2.2. Secondary Dysmenorrhea

6. Regional Analysis

• 6.1. North America
  • 6.1.1. US
  • 6.1.2. Canada
• 6.2. Europe
  • 6.2.1. UK
  • 6.2.2. Germany
  • 6.2.3. Italy
  • 6.2.4. Spain
  • 6.2.5. France
  • 6.2.6. Rest of Europe
• 6.3. Asia-Pacific
  • 6.3.1. China
  • 6.3.2. India
  • 6.3.3. Japan
  • 6.3.4. ASEAN
  • 6.3.5. South Korea
  • 6.3.6. Rest of Asia-Pacific
• 6.4. Rest of the World

7. Company Profiles

• 7.1. Bayer AG
• 7.2. F. Hoffmann-La Roche Ltd
• 7.3. SANOFI
• 7.4. Alvogen Iceland
• 7.5. Pfizer Inc.
• 7.6. ObsEva
• 7.7. Nobelpharma Co., Ltd
• 7.8. Color Seven Co., Ltd.
• 7.9. Sun Pharmaceutical Industries Limited
• 7.10. Beurer GmbH
• 7.11. Abbott Laboratories
• 7.12. Taj Pharmaceuticals Ltd
• 7.13. Myovant Sciences GmbH
• 7.14. AbbVie Inc.
• 7.15. Janssen Pharmaceuticals, Inc.
• 7.16. At Lupin Inc.
• 7.17. Cumberland Pharmaceuticals Inc.
• 7.18. BioElectronics Corporation
• 7.19. GlaxoSmithKline plc.
• 7.20. Merck & Co., Inc.